0001628280-21-015950.txt : 20210805 0001628280-21-015950.hdr.sgml : 20210805 20210805180821 ACCESSION NUMBER: 0001628280-21-015950 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210803 FILED AS OF DATE: 20210805 DATE AS OF CHANGE: 20210805 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lisicki Robert CENTRAL INDEX KEY: 0001779614 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-31161 FILM NUMBER: 211149886 MAIL ADDRESS: STREET 1: C/O ARENA PHARMACEUTICALS, INC. STREET 2: 6154 NANCY RIDGE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ARENA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001080709 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 232908305 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6154 NANCY RIDGE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-453-7200 MAIL ADDRESS: STREET 1: 6154 NANCY RIDGE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 wf-form4_162820124726591.xml FORM 4 X0306 4 2021-08-03 0 0001080709 ARENA PHARMACEUTICALS INC ARNA 0001779614 Lisicki Robert C/O ARENA PHARMACEUTICALS, INC. 6154 NANCY RIDGE DRIVE SAN DIEGO CA 92121 0 1 0 0 EVP, Chief Commercial Officer Common Stock 2021-08-03 4 M 0 17500 40.95 A 33601 D Common Stock 2021-08-03 4 S 0 5605 59.84 D 27996 D Common Stock 2021-08-03 4 S 0 11895 60.20 D 16101 D Employee Stock Option (right to buy) 40.95 2021-08-03 4 M 0 17500 0 D 2025-11-26 Common Stock 17500.0 110000 D The transactions reported in this line item of this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.63 to $59.99, inclusive. The reporting person undertakes to provide Arena Pharmaceuticals, Inc., any security holder of Arena Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.74, inclusive. The options vest over four years, with 25% of the shares subject to the option vesting on November 26, 2019, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested. /s/ Andrew J. Cronauer, as Attorney-in-Fact 2021-08-05